Related Experiment Video
Updated: Mar 17, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
3.0K
Liquid Biopsies for Assessing Metastatic Melanoma Progression
1Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA 90404.
Critical Reviews in Oncogenesis
|August 3, 2016
Summary
Genomic biomarkers in melanoma, including circulating tumor DNA (ctDNA), offer a noninvasive liquid biopsy approach. These blood tests show prognostic utility for assessing tumor progression and guiding treatment, despite ongoing standardization challenges.
Area of Science:
- Genomic Medicine
- Oncology
- Molecular Diagnostics
Background:
- Melanoma research has shifted from tissue-based analysis to liquid biopsies.
- Circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) are key components of liquid biopsies.
- Liquid biopsies offer noninvasive monitoring of tumor progression and treatment response.
Purpose of the Study:
- To review the evolution and potential of genomic biomarkers in melanoma.
- To highlight the advantages of blood-based assays over traditional tissue biopsies.
- To discuss the clinical utility and future directions of liquid biopsy in melanoma management.
Main Methods:
- Review of existing literature on genomic biomarkers in melanoma.
- Focus on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) detection.
- Analysis of technologies for isolating and detecting biomarkers in blood samples.
Main Results:
- Blood-based genomic biomarker assays demonstrate significant clinical prognostic utility.
- Noninvasive nature allows for serial monitoring, addressing tissue heterogeneity.
- Next-generation sequencing and genome-wide ctDNA analysis are advancing the field.
Conclusions:
- Liquid biopsies are a promising tool for melanoma assessment and treatment monitoring.
- Standardization of technologies is needed to overcome current challenges.
- Genomic biomarkers will improve understanding of tumor progression and resistance, leading to better therapeutic strategies.
